AbbVie Faces Questions About Skyrizi Competition From J&J

Why It Matters

The rivalry could reshape market share in the lucrative psoriasis segment, influencing pricing, R&D focus, and investor confidence in AbbVie’s growth trajectory.

Key Takeaways

• Skyrizi Q1 sales hit $1.2 billion, up 12% YoY
• J&J's new IL‑23 inhibitor targets same psoriasis market
• AbbVie expects Skyrizi to reach $5 billion by 2026
• Analysts demand clearer strategy against J&J competition
• Humira biosimilar loss adds pressure on immunology pipeline

Pulse Analysis

AbbVie’s immunology business has long been anchored by Humira, but the company’s future growth now hinges on newer biologics like Skyrizi. The drug’s Q1 performance—$1.2 billion in sales and double‑digit growth—demonstrates strong adoption among dermatology patients, yet the looming entry of Johnson & Johnson’s IL‑23 inhibitor threatens to fragment the market. Investors are watching how AbbVie will differentiate Skyrizi, whether through label expansions, combination therapies, or pricing tactics, to maintain its momentum.

The competitive landscape is intensifying as J&J leverages its extensive sales force and established brand equity with Stelara, while also advancing a next‑generation IL‑23 molecule aimed at the same psoriasis and Crohn’s disease indications. This head‑to‑head battle could compress pricing and accelerate the shift toward biosimilar uptake, especially as Humira’s patent cliffs erode revenue streams. AbbVie’s guidance of $5 billion in Skyrizi sales by 2026 reflects confidence in its pipeline, but achieving that target will require strategic wins against J&J’s forthcoming launch.

From a broader industry perspective, the Skyrizi‑J&J rivalry underscores the importance of innovation speed and market access strategies in biologics. Companies must balance robust clinical data with payer negotiations and real‑world evidence to secure formulary placement. For stakeholders, the outcome will influence not only company valuations but also the therapeutic options available to patients, making the next few quarters critical for AbbVie’s immunology outlook.